A new pathologic scoring system that accurately assesses how much lung tumor is left after a patient receives presurgical cancer treatments can be used to predict survival, according to new research led by investigators at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center and the Mark Foundation...
Reviewed by Lily Ramsey, LLMNov 6 2023 A new pathologic scoring system that accurately assesses how much lung tumor is left after a patient receives presurgical cancer treatments can be used to predict survival, according to new research led by investigators at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center and the Mark Foundation Center for Advanced Genomics and Imaging at the Johns Hopkins University.
Immunotherapies harness a patient's immune system to target their tumors. These powerful drugs are often paired with conventional chemotherapies to help shrink a patient's tumors before surgery, increasing the likelihood of successfully eliminating the cancer. To gauge treatment success, oncologists typically rely on radiologic imaging of the remaining tumor, but the results aren't always as accurate in early-stage tumors as they are for more advanced cancers.
As a result, they were able to separate patients into three groups based on how much tumor was left. In the future, data such as these may help guide the next round of clinical trials and ultimately help oncologists decide how to treat individuals in these subgroups, Deutsch says. For example, patients with no tumor left may be able to skip postsurgical immunotherapy or have a relatively limited amount, while individuals in the intermediate group may need to continue immunotherapy for longer.
"The common features seen across these multiple tumor types means that pathologists don't have to switch to different scoring systems for assessing pathologic response. This is similar to what already exists in radiology, where the RECIST system is used across all tumor types for determining objective response to therapy," Taube says, noting that pathologists already are completing the necessary workflows as part of standard procedures when assessing surgically removed tumors.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Novel urine-based test offers new hope for bladder cancer patientsBladder cancer, notorious for being one of the most costly malignancies to manage, often results in patient discomfort and frequent invasive and expensive procedures.
続きを読む »
A new gene classification system for gastric cancerA research team has announced a new genetic classification system for gastric cancer by a multicenter study with the University of Texas MD Anderson Cancer Center. This research could lay the foundation for personalized gastric cancer treatment.
続きを読む »
First in human trial of new drug raises hopes for patients with relapsed blood cancerA new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J.
続きを読む »
New breast pain clinic launches in Preston aimed at stopping unnecessary cancer anxietyA new breast pain clinic has launched to support women in central Lancashire.
続きを読む »
Targeted drug may offer a new treatment option for patients with relapsed blood cancerA new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J.
続きを読む »
Starbucks new Holiday Menu features returning favourites and new flavoursThere are drinks to pick up in superarkets as well as new food and drinks in branches - and merch
続きを読む »